Sie sind hier: Startseite Archiv Guidelines

Guidelines

Abirateronacetat (Zytiga®)
Abirateronacetat (Zytiga®)
Abirateronacetat (Zytiga®) nach Docetaxel
Afatinib (Giotrif®)
Apixaban (Eliquis®)
Apixaban (Eliquis®)
Axitinib (Inlyta®)
Axitinib (Inlyta®)
Blinatumomab (Blincyto®)
Brentuximab Vedotin (Adcetris®)
Cabazitaxel (Jevtana®)
Cabazitaxel (Jevtana®)
Carfilzomib (Kyprolis®)
Carfilzomib (Kyprolis®)
Carfilzomib (Kyprolis®), Dexamethason
Ceritinib (Zykadia®)
Crizotinib (Xalkori®)
Crizotinib (Xalkori®)
Crizotinib (Xalkori®) Zweitlinientherapie
Dabrafenib (Tafinlar®)
Elotuzumab (Empliciti®)
Enzalutamid (Xtandi®)
Eribulin (Halaven®)
Ibrutinib (Imbruvica®)
Ibrutinib (Imbruvica®) bei CLL
Ibrutinib (Imbruvica®) bei Mantelzell-Lymphom
Idelalisib (Zydelig®)
Idelalisib (Zydelig®) bei CLL
Idelalisib (Zydelig®) bei Follikulärem Lymphom
Ipilimumab (Yervoy®)
Isavuconazol (Cresemba®)
Ixazomib (Ninlaro®)
Lenvatinib (Kisplyx®)
Lenvatinib (Lenvima®)
Lonoctocog alfa (Afstyla®)
Necitumumab (Portrazza®)
Netupitant / Palonosetron (Akynzeo®)
Nintedanib (Vargatef®)
Nivolumab (Opdivo®)
Nivolumab (Opdivo®)
Nivolumab (Opdivo®)
Nivolumab (Opdivo®)
Nivolumab (Opdivo®)
Nivolumab (Opdivo®) bei Lungenkarzinom, nicht-kleinzellig (NSCLC), Plattenepithelkarzinom
Obinutuzumab (Gazyvaro™) bei Follikulärem Lymphom
Olaparib (Lynparza™)
Osimertinib (Tagrisso®)
Osimertinib (Tagrisso®)
Panobinostat (Farydak®)
Pembrolizumab (Keytruda®)
Pembrolizumab (Keytruda®) bei Melanom
Pertuzumab (Perjeta®)
Pertuzumab (Perjeta®)
Pixantron (Pixuvri®)
Pomalidomid (Imnovid®)
Pomalidomid (Imnovid®)
Ponatinib (Iclusig®)
Radium-223 (Xofigo®)
Ramucirumab (Cyramza®)
Ramucirumab (Cyramza®)
Ramucirumab (Cyramza®)
Regorafenib (Stivarga®)
Regorafenib (Stivarga®) bei kolorektalem Karzinom
Ruxolitinib (Jakavi®)
Ruxolitinib (Jakavi®)
Siltuximab (Sylvant®)
Trastuzumab Emtansin (Kadcyla®)
Vemurafenib (Zelboraf®)
Venetoclax (Venclyxto®)
Vismodegib (Erivedge®)